Description
An orally bioavailable inhibitor of HDAC1, HDAC3, and HDAC6 (IC50s = 43-72 nM), resulting in hyperacetylation of histone H4 in multiple myeloma cells; abrogates cell growth and strongly induces apoptosis in multiple myeloma cells (IC50s = 2.5-3 µM); dose-dependently inhibits HDAC activity in vivo